261 research outputs found
Report No. 24: Analysis of the Social Agendas
Study conducted for the European Parliament, Bonn 2010 (135 pages)
Report No. 29: The Mobility and Integration of People with Disabilities into the Labour Market
Report based on a study conducted for the European Parliament, Bonn 2010 (95 pages)
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL
Our objective was to evaluate minimal residual disease (MRD) at the end of induction treatment with chemoimmunotherapy as a surrogate end point for progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) based on 3 randomized, phase 3 clinical trials (ClinicalTrials.gov identifiers NCT00281918, NCT00769522, and NCT02053610). MRD was measured in peripheral blood (PB) from treatment-naĂŻve patients in the CLL8, CLL10, and CLL11 clinical trials, and quantified by 4-color flow cytometry or allele-specific oligonucleotide real-time quantitative polymerase chain reaction. A meta-regression model was developed to predict treatment effect on PFS using treatment effect on PB-MRD. PB-MRD levels were measured in 393, 337, and 474 patients from CLL8, CLL10, and CLL11, respectively. The model demonstrated a statistically significant relationship between treatment effect on PB-MRD and treatment effect on PFS. As the difference between treatment arms in PB-MRD response rates increased, a reduction in the risk of progression or death was observed; for each unit increase in the (log) ratio of MRD2 rates between arms, the log of the PFS hazard ratio decreased by 20.188 (95% confidence interval, 20.321 to 20.055; P 5 .008). External model validation on the REACH trial and sensitivity analyses confirm the robustness and applicability of the surrogacy model. Our surrogacy model supports use of PB-MRD as a primary end point in randomized clinical trials of chemoimmunotherapy in CLL. Additional CLL trial data are required to establish a more precise quantitative relationship between MRD and PFS, and to support general applicability of MRD surrogacy for PFS across diverse patient characteristics, treatment regimens, and different treatment mechanisms of action
VenetoclaxâRituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Background: Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Methods: In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclaxârituximab group) or bendamustine plus rituximab for 6 months (bendamustineârituximab group). The trial design did not include crossover to venetoclax plus rituximab for patients in the bendamustineârituximab group in whom progression occurred. The primary end point was investigator-assessed progression-free survival.
Results: After a median follow-up period of 23.8 months, the rate of investigator-assessed progression-free survival was significantly higher in the venetoclaxârituximab group (32 events of progression or death in 194 patients) than in the bendamustineârituximab group (114 events in 195 patients); the 2-year rates of progression-free survival were 84.9% and 36.3%, respectively (hazard ratio for progression or death, 0.17; 95% confidence interval [CI], 0.11 to 0.25; P<0.001 by the stratified log-rank test). The benefit was maintained across all clinical and biologic subgroups, including the subgroup of patients with chromosome 17p deletion; the 2-year rate of progression-free survival among patients with chromosome 17p deletion was 81.5% in the venetoclaxârituximab group versus 27.8% in the bendamustineârituximab group (hazard ratio, 0.13; 95% CI, 0.05 to 0.29), and the 2-year rate among those without chromosome 17p deletion was 85.9% versus 41.0% (hazard ratio, 0.19; 95% CI, 0.12 to 0.32). The benefit of venetoclax plus rituximab over bendamustine plus rituximab was confirmed by an independent review committee assessment of progression-free survival and other secondary efficacy end points. The rate of grade 3 or 4 neutropenia was higher in the venetoclaxârituximab group than in the bendamustineârituximab group, but the rates of grade 3 or 4 febrile neutropenia and infections or infestations were lower with venetoclax than with bendamustine. The rate of grade 3 or 4 tumor lysis syndrome in the venetoclaxârituximab group was 3.1% (6 of 194 patients).
Conclusions: Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab. (Funded by Genentech and AbbVie; ClinicalTrials.gov number, NCT02005471.
The evolving landscape of COVIDâ19 and postâCOVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL
In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, pâ=â.0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7âmonths. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41â0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02â1.04; HR = 1.79, 95% CI:1.04â3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated
Ibrutinib frontline in young patients with CLL
In this issue of Blood, Shanafelt et al(1) confirm the continued superiority of ibrutinib plus rituximab (IR), compared with the prior standard treatment, fludarabine, cyclophosphamide, and rituximab (FCR), for fit patients with chronic lymphocytic leukemia (CLL). In addition, they report relevant data on the tolerability of continuous treatment with BTK inhibitor
Vaccination against COVID-19: a challenge in CLL
In this issue of Blood, Herishanu et al report on the efficacy of the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine in untreated and treated patients with chronic lymphocytic leukemia (CLL).(1) Their findings show low response rates to vaccination in CLL, similar to previous reports with other vaccines
Novel therapy concepts for chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the western hemisphere and affects mainly elderly and male patients. There is currently no curative approach for advanced symptomatic stages of the disease despite great progress in treatment. Treatment is determined according to patient fitness and comorbidity burden as well as the presence of deletions or mutations in the TP53 gene (very high risk CLL). In physically fit patients without a high comorbidity burden and without very high risk prognostic factors intensive chemotherapy in combination with the CD20 antibody is the standard first line therapy, while in patients with a significant comorbidity burden a less intensive immunochemotherapy regimen is applied. In very high risk patients as well as in patients with relapsed CLL two oral kinase inhibitors, which block the signaling transduction pathway of the B cell receptor have been approved; however, in relapsed CLL repeat administration of immunochemotherapy is still an alternative treatment option, especially if the first remission period was of longer duration (> 24 months). Allogeneic hematopoietic stem cell transplantation can be considered in high risk CLL patients with insufficient response to kinase inhibitors
- âŚ